Lyell Immunopharma (NASDAQ:LYEL) Trading Down 5.8%

Lyell Immunopharma, Inc. (NASDAQ:LYELGet Free Report) traded down 5.8% on Wednesday . The stock traded as low as $2.57 and last traded at $2.59. 158,863 shares were traded during trading, a decline of 83% from the average session volume of 926,034 shares. The stock had previously closed at $2.75.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Lyell Immunopharma in a research report on Tuesday, May 7th.

View Our Latest Stock Analysis on Lyell Immunopharma

Lyell Immunopharma Stock Down 6.9 %

The company’s fifty day simple moving average is $2.39 and its two-hundred day simple moving average is $2.17. The company has a market capitalization of $652.65 million, a price-to-earnings ratio of -2.92 and a beta of -0.54.

Lyell Immunopharma (NASDAQ:LYELGet Free Report) last posted its earnings results on Monday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Lyell Immunopharma had a negative net margin of 335,794.09% and a negative return on equity of 33.92%. Equities research analysts expect that Lyell Immunopharma, Inc. will post -0.85 earnings per share for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors have recently modified their holdings of the business. ProShare Advisors LLC grew its position in Lyell Immunopharma by 9.3% during the first quarter. ProShare Advisors LLC now owns 48,986 shares of the company’s stock worth $109,000 after buying an additional 4,170 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Lyell Immunopharma by 13.2% in the third quarter. Principal Financial Group Inc. now owns 68,080 shares of the company’s stock worth $100,000 after purchasing an additional 7,915 shares during the period. Profund Advisors LLC raised its stake in Lyell Immunopharma by 20.0% in the third quarter. Profund Advisors LLC now owns 73,442 shares of the company’s stock valued at $108,000 after purchasing an additional 12,225 shares in the last quarter. Public Employees Retirement System of Ohio grew its stake in Lyell Immunopharma by 109.7% during the third quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock worth $40,000 after buying an additional 14,229 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Lyell Immunopharma in the 4th quarter valued at approximately $31,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

(Get Free Report)

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

Further Reading

Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.